Weixiu Luo

Biostatistician at Dana-Farber Cancer Institute and Clinical Epidemiologist at United BioSource Corporation

Woburn, Massachusetts (Greater Boston Area)

As a LinkedIn member, you'll join 300 million other professionals who are sharing connections, ideas, and opportunities.

  • See who you and Weixiu Luo know in common
  • Get introduced to Weixiu Luo
  • Contact Weixiu Luo directly

View Weixiu's full profile

Weixiu Luo's Overview

  • Clinical Epidemiologist at United BioSource Corporation
  • Biostatistician at Dana-Farber Cancer Institute
  • Graduate Consultant at Penn State Statistical Consulting Center
  • Physician at Beijing Binhe Hospital

6 connections

Weixiu Luo's Summary

I have been working in the field of clinical trials, pharmaceutical and healthcare research for seven years in US. I had almost one and a half years of experience as a Biostatistician in Dana-Farber Cancer Institute, working on all phases of clinical trials for Eastern Cooperative Oncology Group (ECOG), clinical and laboratory studies for Dana-Farber/Harvard Cancer Center (DF/HCC) and Center for AIDS Research (CFAR) of Harvard Medical School. More recently, I have over five years of experience as a Clinical Epidemiologist in United BioSource Corporation (UBC), a global scientific and medical affairs organization, serving as Principle Investigator on clinical and healthcare research projects sponsored by pharmaceutical/biotech companies. In this position I worked extensively on Electronic Medical Records (EMRs) data analysis and literature reviews.

I obtained Master of Science degree in Statistics in Pennsylvania State University in 2004. Before that, I completed five-year training in Clinical Medicine, obtained my medical degree in China Medical University in 1997, and had been practicing internal medicine as a physician in China for three and a half years.

Weixiu Luo's Experience

Clinical Epidemiologist

United BioSource Corporation

Public Company; 1001-5000 employees; Hospital & Health Care industry

January 2006May 2011 (5 years 5 months) Lexington, MA

I worked as a principal investigator on pharmaceutical and epidemiologic projects with specific expertise and focus in oncology-related projects for UBC’s Center for Epidemiology and Database Analytics (CEDA). The projects involved analyses of electronic medical records (EMRs) data or systematic literature review and meta-analysis to address research questions to inform and support decisions, strategies, and messages in drug development, regulatory and marketing.
1) For the projects involving analyses of EMR data, I defined clinical research questions with clients, looked into EMR database and assessed feasibility of a project, wrote protocol, designed table shells, performed logic and common sense check to queried data for validity and completeness, applied clinical expertise to standardize queried database, define data conventions and algorithms prior to data analysis (such as rules for identifying cancer diagnosis, cancer staging, comorbidities, algorithms for defining chemotherapy regimens and cycles in the longitudinal EMR database, etc.), interpreted and presented study results to clients, wrote project reports, prepared abstracts and posters for conferences, and wrote manuscripts for publications.
2) For systematic literature review projects, I defined clinical research questions, wrote protocol, designed data extraction forms (DEFs) and table shells, collected and screened publications for systematic review, extracted clinical information from published literatures, conducted consensus of extraction with other medical doctors, collaborated with statisticians on meta-analyses, interpreted and reported study results to clients, wrote project reports and manuscripts for publications.

Nonprofit; 1001-5000 employees; Hospital & Health Care industry

September 2004January 2006 (1 year 5 months)

I served as
1) Statistician at Statistical Center of Eastern Cooperative Oncology Group (ECOG) funded by NIH/NCI, working on all phases of ECOG clinical trials. Main responsibilities include providing study design and statistical considerations in protocol, collaborating with principle investigators and interacting with NCI in protocol development and activation, developing and reviewing case report forms, monitoring active studies (accrual, efficacy, toxicity, etc.), preparing biannual interim reports, DMC reports and grant progress report, working with data specialists to prepare data for analysis, writing programs in SAS, Splus/R or other languages as needed, performing data analysis and writing technical reports, preparing and reviewing manuscripts and meeting abstracts, assisting clinical investigators in use of ECOG database for research into natural history and patho-physiology;
2) Statistician at Dana-Farber/Harvard Cancer Center (DF/HCC), providing consultation and collaboration on all types of laboratory and clinical cancer studies, working closely with medical doctors and research scientists on study design, protocol development, data analysis and reporting, providing statistical input and assistance for publications;
3) Statistician at Center for AIDS Research (CFAR) of Harvard Medical School, providing statistical collaborations and consultation on HIV research studies.

Graduate Consultant

Penn State Statistical Consulting Center

September 2003May 2004 (9 months) University Park, PA

Responsibilities include
1) providing statistical support for research projects for Penn State faculty, graduate students and non-university affiliated research organizations
2) instructing undergraduate students to provide consulting services to their clients


Beijing Binhe Hospital

September 1997December 2000 (3 years 4 months) Beijing, China

Physician in the Department of Cardiac-Cerebral Vascular Internal Medicine and the Intensive/Cardiac Care Unit (ICU/CCU)

Weixiu Luo's Projects

  • E1299: A Phase II Study of ORZEL (UFT + Leucovorin) in Elderly (≥ 75 years old) Patients with Colorectal Cancer

    Team Members: Weixiu Luo
  • E4201: A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy versus Gemcitabine Alone in Patients with Localized, Unresectable Pancreatic Cancer

    Team Members: Weixiu Luo
  • E6202: A Phase II Trial of Bortezomib Plus Doxorubicin in Hepatocellular Carcinoma

    Team Members: Weixiu Luo
  • E8200: A Phase II Trial of Irinotecan/Docetaxel for Advanced Pancreatic Cancer, with Randomization Between Irinotecan/ Docetaxel and Irinotecan/Docetaxel Plus C225 a Monoclonal Antibody to the Epidermal Growth Factor Receptor (EGF-r)

    Team Members: Weixiu Luo
  • E1603: Phase II Trial of Depsipeptide (NSC 630176) in Advanced Malignant Melanoma

    Team Members: Weixiu Luo
  • E2602: Phase II Study of Low Dose Peginterferon Alfa-2b in Patients with Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor

    Team Members: Weixiu Luo
  • Phase II Study of BAY43-9006 (Sorafenib) Combined with Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Unresectable Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinoma

    Team Members: Weixiu Luo
  • Phase II Study of Preoperative Radiation with Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients with Locally Advanced Rectal Cancer

    Team Members: Weixiu Luo
  • Phase II Trial of Selective Internal Radiation Therapy (SIRT) with SIR-Spheres in Metastatic Colorectal Cancer (CRC) and Hepatocellular Cancer (HCC)

    Team Members: Weixiu Luo
  • A Randomized phase II/III Trial Evaluating Gemcitabine/Oxaliplatin in Combination with Bevacizumab, Cetuximab or Both in Patients with Metastatic Adenocarcinoma of the Pancreas

    Team Members: Weixiu Luo
  • Variability Among Breast Radiation Oncologists in Delineation of the Post-Surgical Breast Lumpectomy Cavity Volume

    Team Members: Weixiu Luo
  • A Partial Breast Irradiation Study to Evaluate Target Registration Error (TRE) of 3D Surface Imaging Method Compared to Laser and Chest Wall Methods and to Investigate Factors that Influence TRE

    Team Members: Weixiu Luo
  • Impact of Sulindac on Tumor-Promoting Effect of Stroma (MOP) in Mice

    Team Members: Weixiu Luo
  • BRCA1/BARD1- Mediated Association of RCC1 with Chromatin Is Required for the Fidelity of Mitosis and Mitotic Exit

    Team Members: Weixiu Luo
  • A Study of Central Memory and Effector Memory p11C+ CD8 T Cells in HIV Infected Monkeys

    Team Members: Weixiu Luo
  • A Study to Evaluate Efficacy of Three Types of Vaccines and Effect of Vaccine Dose Levels on Viral Load in Monkeys Infected with HIV

    Team Members: Weixiu Luo

Weixiu Luo's Certifications

  • Licensed Doctor in China (M.D. equivalent)

    • Ministry of Health P.R. China
    • November 2000

Weixiu Luo's Publications

  • Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials.

    • Am J Clin Pathol. 133(4):646-53
    • April 2010
    Authors: Weixiu Luo, Rao UN, Lee SJ
  • Synchronization of Treatment with Erythropoiesis-Stimulating Agents and Chemotherapy.

    • Am J Pharm Benefits. 2(3):199-208
    • 2010
    Authors: Weixiu Luo, Nordstrom BL, Fraeman KH
  • Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.

    • Clin Ther. 30(12):2423-35
    • December 2008
    Authors: Weixiu Luo, Nordstrom BL, Fraeman K
  • Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.

    • J Manag Care Pharm. 14(9):858-69
    • November 2008
    Authors: Weixiu Luo, Nordstrom BL, Fraeman K
  • Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299.

    • J Clin Oncol. 25(34):5397-402
    • December 1, 2007
    Authors: Weixiu Luo, Hochster HS, Popa EC
  • Variability among breast radiation oncologists in delineation of the postsurgical lumpectomy cavity.

    • Int J Radiat Oncol Biol Phys. 67(5):1299-308
    • April 1, 2007
    Authors: Weixiu Luo, Landis DM, Song J

Weixiu Luo's Languages

  • English

    (Full professional proficiency)
  • Chinese

    (Native or bilingual proficiency)

Weixiu Luo's Skills & Expertise

  1. Statistical programming skill in SAS
  2. Other statistical programming languages and software including R, Splus
  3. Experience in working with large relational database including Oracle Clinical
  4. Microsoft windows and Unix working environments

Weixiu Luo's Education

Pennsylvania State University

Master of Science (M.S.), Statistics


China Medical University

Doctor of Medicine (M.D.), Clinical Medicine


Contact Weixiu for:

View Weixiu Luo’s full profile to...

  • See who you and Weixiu Luo know in common
  • Get introduced to Weixiu Luo
  • Contact Weixiu Luo directly

View Weixiu's full profile

Viewers of this profile also viewed...